Top

Published in:

01-01-2021 | Systemic Sclerosis | Epidemiology of RMD

Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data

Authors: Jacopo Ciaffi, Maria Francesca Morabito, Piero Ruscitti, Salvatore D’Angelo, Luana Mancarella, Veronica Brusi, Giuseppina Abignano, Valentina Pucino, Roberto Giacomelli, Riccardo Meliconi, Francesco Ursini

Published in: Rheumatology International | Issue 1/2021

Abstract

To study incidence, prevalence and mortality of systemic sclerosis (SSc) in Italy, assessing epidemiological differences between men and women and in distinct age groups. We performed a nationwide population-based study using administrative health data from regional co-payment exemption registries. Patients entitled with SSc-specific co-payment exemption were included. Fourteen of the 20 Italian regions contributed data covering a population of over 45 million individuals. Crude annual incidence rate, annual prevalence, crude annual mortality rate and standardised mortality ratio (SMR) were calculated. In 2016, the overall crude incidence rate of SSc was 18.5 (95% CI 16.9–20.2) per million per year. Incidence rate was 31.0 (95% CI 28.1–34.1) per million in women, and 4.3 (95% CI 3.2–5.6) per million in men. Peak incidence was observed in the age range 55–69 years. Overall annual prevalence was 306.1 (95% CI 301.1–311.2) per million. Prevalence was 530.8 (95% CI 521.5–540.2) per million in women and 67.8 (95% CI 64.4–71.3) per million in men, with a female to male ratio of 7.8:1. Highest prevalence was observed in the range 70–84 years. Crude annual mortality rate was 27.9 (95% CI 24.9–31.1) per 1000 patients. Overall SMR in patients with SSc was 2.8 (95% CI 1.9–3.8). SMR was 3.8 (95% CI 2.9–5.1) in men and 2.6 (95% CI 1.8–3.6) in women. We provided updated estimates on epidemiology of SSc in Italy. Our findings on incidence, prevalence and mortality of SSc are consistent with previously published literature.

Denton CP, Khanna D (2017) Systemic sclerosis. Lancet (London, England) 390(10103):1685–1699. https://doi.org/10.1016/s0140-6736(17)30933-9CrossRef

Wollheim FA (2005) Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford, England) 44 (10):1212–1216. https://doi.org/10.1093/rheumatology/keh671

Bergamasco A, Hartmann N, Wallace L, Verpillat P (2019) Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol 11:257–273. https://doi.org/10.2147/clep.S191418CrossRefPubMedPubMedCentral

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980). Arthritis Rheum. 23(5):581–590. https://doi.org/10.1002/art.1780230510

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed

LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573–1576PubMed

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Muller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747. https://doi.org/10.1002/art.38098CrossRefPubMedPubMedCentral

Lo Monaco A, Bruschi M, La Corte R, Volpinari S, Trotta F (2011) Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol 29(2 Suppl 65):S10-14PubMed

Arias-Nunez MC, Llorca J, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Martin J, Gonzalez-Juanatey C, Gonzalez-Gay MA (2008) Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine 87(5):272–280. https://doi.org/10.1097/MD.0b013e318189372fCrossRefPubMed

10.

Andreasson K, Saxne T, Bergknut C, Hesselstrand R, Englund M (2014) Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis 73(10):1788–1792. https://doi.org/10.1136/annrheumdis-2013-203618CrossRefPubMed

11.

Iannazzo S, Furneri G, Demma F, Distante C, Parisi S, Berti V, Fusaro E (2016) The burden of rheumatic diseases: an analysis of an Italian Administrative Database. Rheumatol Ther 3(1):167–177. https://doi.org/10.1007/s40744-016-0034-2CrossRefPubMedPubMedCentral

12.

Carrara G, Scire CA, Zambon A, Cimmino MA, Cerra C, Caprioli M, Cagnotto G, Nicotra F, Arfe A, Migliazza S, Corrao G, Minisola G, Montecucco C (2015) A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology. BMJ Open 5(1):e006029. https://doi.org/10.1136/bmjopen-2014-006029

13.

Giorda CB, Carna P, Romeo F, Costa G, Tartaglino B, Gnavi R (2017) Prevalence, incidence and associated comorbidities of treated hypothyroidism: an update from a European population. Eur J Endocrinol 176(5):533–542. https://doi.org/10.1530/eje-16-0559CrossRefPubMed

14.

Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M (2016) Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. J Neurol 263(4):751–759. https://doi.org/10.1007/s00415-016-8049-8CrossRefPubMedPubMedCentral

15.

Di Domenicantonio R, Cappai G, Arca M, Agabiti N, Kohn A, Vernia P, Biancone L, Armuzzi A, Papi C, Davoli M (2014) Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. Digest Liver Dis 46(9):777–782. https://doi.org/10.1016/j.dld.2014.04.014CrossRef

16.

Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26(4):404–413. https://doi.org/10.2307/2331986CrossRef

17.

Airò P, Tabaglio E, Frassi M, Scarsi M, Danieli E, Rossi M (2007) Prevalence of systemic sclerosis in Valtrompia in northern Italy. A collaborative study of rheumatologists and general practitioners. Clin Exp Rheumatol 25 (6):878–880

18.

Airò P, Regola F, Lazzaroni MG, Tincani A, Inverardi F, Fenini MG, Ferre F, Furloni R, Scarsi M (2019) Incidence and prevalence of systemic sclerosis in Valcamonica, Italy, during an 18-year period. J Scleroderma Relat Disord 5(1):51–56. https://doi.org/10.1177/2397198318819908

19.

Piga M, Casula L, Sanna S, Perra D, Floris A, Antonelli A, Cauli A, Mathieu A (2016) Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001–2012. Rheumatol Int 36(1):73–81. https://doi.org/10.1007/s00296-015-3330-1CrossRefPubMed

20.

Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA, Drosos AA (2005) Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 34(5):714–720. https://doi.org/10.1016/j.semarthrit.2004.09.001CrossRefPubMed

21.

Radic M, Martinovic Kaliterna D, Fabijanic D, Radic J (2010) Prevalence of systemic sclerosis in Split-Dalmatia county in Southern Croatia. Clin Rheumatol 29(4):419–421. https://doi.org/10.1007/s10067-009-1341-6CrossRefPubMed

22.

Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L (2004) Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford, England) 43(9):1129–1137. https://doi.org/10.1093/rheumatology/keh253CrossRef

23.

El Adssi H, Cirstea D, Virion JM, Guillemin F, de Korwin JD (2013) Estimating the prevalence of systemic sclerosis in the Lorraine region, France, by the capture-recapture method. Semin Arthritis Rheum 42(5):530–538. https://doi.org/10.1016/j.semarthrit.2012.10.001CrossRefPubMed

24.

Royle JG, Lanyon PC, Grainge MJ, Abhishek A, Pearce FA (2018) The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol 37(8):2103–2111. https://doi.org/10.1007/s10067-018-4182-3CrossRefPubMedPubMedCentral

25.

Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID (2004) A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford, England) 43(5):596–602. https://doi.org/10.1093/rheumatology/keh124CrossRef

26.

Vonk MC, Broers B, Heijdra YF, Ton E, Snijder R, van Dijk AP, van Laar JM, Bootsma H, van Hal PT, van den Hoogen FH, van Daele PL (2009) Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 68(6):961–965. https://doi.org/10.1136/ard.2008.091710CrossRefPubMed

27.

Eaton WW, Pedersen MG, Atladottir HO, Gregory PE, Rose NR, Mortensen PB (2010) The prevalence of 30 ICD-10 autoimmune diseases in Denmark. Immunol Res 47(1–3):228–231. https://doi.org/10.1007/s12026-009-8153-2CrossRefPubMedPubMedCentral

28.

Hoffmann-Vold AM, Midtvedt O, Molberg O, Garen T, Gran JT (2012) Prevalence of systemic sclerosis in south-east Norway. Rheumatology (Oxford, England) 51(9):1600–1605. https://doi.org/10.1093/rheumatology/kes076CrossRef

29.

Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 81(2):139–153. https://doi.org/10.1097/00005792-200203000-00004CrossRefPubMed

30.

Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z, Szucs G (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67(1):59–63. https://doi.org/10.1136/ard.2006.066340CrossRefPubMed

31.

Strickland G, Pauling J, Cavill C, Shaddick G, McHugh N (2013) Mortality in systemic sclerosis-a single centre study from the UK. Clin Rheumatol 32(10):1533–1539. https://doi.org/10.1007/s10067-013-2289-0CrossRefPubMed

32.

Bryan C, Howard Y, Brennan P, Black C, Silman A (1996) Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35(11):1122–1126. https://doi.org/10.1093/rheumatology/35.11.1122CrossRefPubMed

33.

Hussein H, Lee P, Chau C, Johnson SR (2014) The effect of male sex on survival in systemic sclerosis. J Rheumatol 41(11):2193–2200. https://doi.org/10.3899/jrheum.140006CrossRefPubMed

34.

Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Lega JC, Allanore Y, Jego P, Bienvenu B, Berthier S, Mekinian A, Hachulla E, Launay D (2019) Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther 21(1):86. https://doi.org/10.1186/s13075-019-1867-1CrossRefPubMedPubMedCentral

35.

Peoples C, Medsger TA Jr, Lucas M, Rosario BL, Feghali-Bostwick CA (2016) Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord 1(2):177–240. https://doi.org/10.5301/jsrd.5000209CrossRefPubMedPubMedCentral

36.

Elhai M, Avouac J, Walker UA, Matucci-Cerinic M, Riemekasten G, Airo P, Hachulla E, Valentini G, Carreira PE, Cozzi F, Balbir Gurman A, Braun-Moscovici Y, Damjanov N, Ananieva LP, Scorza R, Jimenez S, Busquets J, Li M, Muller-Ladner U, Kahan A, Distler O, Allanore Y (2016) A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75(1):163–169. https://doi.org/10.1136/annrheumdis-2014-206386CrossRefPubMed

37.

Hoffmann-Vold AM, Molberg O, Midtvedt O, Garen T, Gran JT (2013) Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol 40(7):1127–1133. https://doi.org/10.3899/jrheum.121390CrossRefPubMed

38.

Butt SA, Jeppesen JL, Fuchs C, Mogensen M, Engelhart M, Torp-Pedersen C, Gislason GH, Jacobsen S, Andersson C (2018) Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. BMC Rheumatol 2:36. https://doi.org/10.1186/s41927-018-0043-6CrossRefPubMedPubMedCentral

39.

Hesselstrand R, Scheja A, Akesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57(11):682–686. https://doi.org/10.1136/ard.57.11.682CrossRefPubMedPubMedCentral

40.

Elhai M, Meune C, Avouac J, Kahan A, Allanore Y (2012) Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford, England) 51(6):1017–1026. https://doi.org/10.1093/rheumatology/ker269CrossRef

41.

Pelkonen PM, Jalanko HJ, Lantto RK, Makela AL, Pietikainen MA, Savolainen HA, Verronen PM (1994) Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol 21(11):2143–2146PubMed

42.

Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM (2010) Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res 62(2):213–218. https://doi.org/10.1002/acr.20070CrossRef

43.

Marino C, Ferraro PM, Bargagli M, Cascini S, Agabiti N, Gambaro G, Davoli M (2020) Prevalence of chronic kidney disease in the Lazio region, Italy: a classification algorithm based on health information systems. BMC Nephrol 21(1):23. https://doi.org/10.1186/s12882-020-1689-zCrossRefPubMedPubMedCentral

44.

Caputo M, Pecere A, Sarro A, Mele C, Ucciero A, Pagano L, Prodam F, Aimaretti G, Marzullo P, Barone-Adesi F (2020) Incidence and prevalence of hyperthyroidism: a population-based study in the Piedmont Region, Italy. Endocrine. 10.1007/s12020-020-02222-7

45.

Gini R, Schuemie MJ, Francesconi P, Lapi F, Cricelli I, Pasqua A, Gallina P, Donato D, Brugaletta S, Donatini A, Marini A, Cricelli C, Damiani G, Bellentani M, van der Lei J, Sturkenboom MC, Klazinga NS (2014) Can Italian healthcare administrative databases be used to compare regions with respect to compliance with standards of care for chronic diseases? PLoS ONE 9(5):e95419. https://doi.org/10.1371/journal.pone.0095419CrossRefPubMedPubMedCentral

Title: Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data
Authors: Jacopo Ciaffi
Maria Francesca Morabito
Piero Ruscitti
Salvatore D’Angelo
Luana Mancarella
Veronica Brusi
Giuseppina Abignano
Valentina Pucino
Roberto Giacomelli
Riccardo Meliconi
Francesco Ursini
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keyword: Systemic Sclerosis
Published in: Rheumatology International / Issue 1/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04720-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Novel mutation in the NRLP3 manifesting as an intermediate phenotype of cryopyrinopathies

Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study

COVID-19 pandemic in Japan

Menorrhagia due to uterine amyloidosis in familial Mediterranean fever: case-based review

Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic

Teleconsultation experience with the idiopathic inflammatory myopathies: a prospective observational cohort study during the COVID-19 pandemic

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page